Should college athletes be paid?
…
continue reading
A weekly podcast for physicians interested in evidence based medicine and rheumatology. Find the papers at ebrheum.com
…
continue reading
1
E114: Target Trials and STAR-RA with Rishi Desai
31:15
31:15
Play later
Play later
Lists
Like
Liked
31:15
Important methodology podcast this week, covering a lot of ground with expert epidemiologist Rishi Desai. Really enjoyed our conversation and glad to be publishing today! **House Keeping Note: we actually recorded this ~15 months ago but I somehow lost the audio... which somehow re-appeared! #technology STAR-RA: https://pubmed.ncbi.nlm.nih.gov/3502…
…
continue reading
Exciting podcast this week about the upcoming / impending use of CAR-T in rheumatology. Highly recommend rheumatologists learn about this now; it's going to be a big thing for many years to come. In a future episode I will lay out my case for skepticism, but for now I think a good run down of the first big published series will be enough! NEJM CAR-…
…
continue reading
This week's podcast will be a quick read of one of my newsletters. The title basically speaks for itself! Find the newsletter and my other work at ebrheum.comBy Michael Putman
…
continue reading
1
E111: PEXIVAS Subsets with Mike Walsh & Mats Junek
39:27
39:27
Play later
Play later
Lists
Like
Liked
39:27
At ACR23 I had a twitter-disagreement about steroid tapers from PEXIVAS with Mike Walsh, the lead author on the PEXIVAS trial. He kindly agreed to join me for a moderated discussion. Loved hearing his perspective and have to admit he pulled me closer to his practice... but not all the way there. Longer podcast than usual but I prefer to release aud…
…
continue reading
1
E110: Rheum4Debate - Screening for RA-ILD with Joshua Solomon and Scott Matson
24:19
24:19
Play later
Play later
Lists
Like
Liked
24:19
Rheum4Debate is back! In this episode I moderated a debate between two pulmonologists about RA-ILD. As a reminder, Rheum4Debate is an Oxford-style debate show, where two debators disagree over a motion during 3 rounds of discussion. The motion for todays show was: “Asymptomatic patients with rheumatoid arthritis and high risk features for interstit…
…
continue reading
1
E109: Abatacept for Pre-RA - the ARIAA Study
16:22
16:22
Play later
Play later
Lists
Like
Liked
16:22
Nice study this week on an important topic. Can we prevent the development of rheumatoid arthritis by initiating DMARDs during a preclinical phase? Lots to discuss: what does it mean to be "pre-clinical?" How does this fit with other studies of this nature? Check it out! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02650-8/ful…
…
continue reading
1
E108: Myositis Guidelines for Cancer Screening w/Alexander Oldroyd
16:04
16:04
Play later
Play later
Lists
Like
Liked
16:04
Informative podcast this week with Dr. Alexander Oldroyd, the first author of the recently published "International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening." The article itself appeared in Nature Reviews Rheumatology and provides what I think is a very useful framework for approaching this issue. Article: https://…
…
continue reading
1
E107: Fragility of SLE Randomized Controlled Trials
13:17
13:17
Play later
Play later
Lists
Like
Liked
13:17
Quick methodology episode this week discussing the concept of "fragility" in randomized controlled trials of lupus. Really enjoyed discussing this paper and was grateful to have been a part of it. Get the text here: https://lupus.bmj.com/content/lupusscimed/11/1/e001068.full.pdfBy Michael Putman
…
continue reading
Today I'm taking another twitter discussion into the podcast realm! Dr. Bhaskar Dasgupta has published hundreds of papers about polymyalgia rheumatica and giant cell arteritis, including a recent publication in Nature Reviews: Rheumatology that piqued my interest (https://www.nature.com/articles/s41584-023-00976-8). In this podcast we discuss scree…
…
continue reading
Interesting topic and interesting paper this year, including discussion of observational biases, positive and negative controls, and interpreting data as it comes. Paper: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810259By Michael Putman
…
continue reading
1
E104: Sarilumab for PMR - The SAPHYR Study
18:35
18:35
Play later
Play later
Lists
Like
Liked
18:35
Important trial on the podcast this week! I take a deep dive into the recently published SAPHYR study, which evaluated the use of the IL6 inhibitor sarilumab for patients with PMR. A few aggravating quibbles but overall a very useful trial and an important step forward for patients with PMR. Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2303…
…
continue reading
1
E103: Len Calabrese on Monoclonal Antibodies for COVID-19
22:25
22:25
Play later
Play later
Lists
Like
Liked
22:25
This week I took a twitter disagreement from the impersonal world of twitter to the podcast world of a back and forth conversation. Really enjoyed talking to Dr. Len Calabrese about monoclonal antibodies, FDA regulatory pathways, and life in general.By Michael Putman
…
continue reading
1
E102: Unintentional Unblinding in Rheumatic Disease Trials
11:31
11:31
Play later
Play later
Lists
Like
Liked
11:31
Excited to share an editorial that I wrote along with Cody Bruggemeyer and Desh Nepal, two trainees with me at the Medical College of Wisconsin. We discussed what I believe to be a pervasive (but seldom discussed) issue in rheumatology RCTs: unblinding. I suspect many of our studies suffer from this. Have a listen!…
…
continue reading
1
E101: Pred v Colchicine for CPPD: COLCHICORT
10:49
10:49
Play later
Play later
Lists
Like
Liked
10:49
Happy to share the FIRST randomized trial in CPPD today. It's kind of a weird study but worth a quick discussion. https://www.sciencedirect.com/science/article/pii/S2665991323001650By Michael Putman
…
continue reading
1
E100: ADVOCATE Health Related Quality of Life
15:35
15:35
Play later
Play later
Lists
Like
Liked
15:35
This week I dive into the health related quality of life measures that were reported in the ADVOCATE study. I found them overall somewhat convincing and they have affected my practice. Have a listen and be sure to follow along. Find my work at ebrheum.comBy Michael Putman
…
continue reading
Quick episode this week from a recent Perspective piece I had published in the New England Journal. Have a listen or a read! https://www.nejm.org/doi/full/10.1056/NEJMp2304828By Michael Putman
…
continue reading
1
E98: Key Opinion Leaders & ILD Guidelines
10:29
10:29
Play later
Play later
Lists
Like
Liked
10:29
Podcast this week discussing key opinion leaders (KOLs) and pharmaceutical companies. Please subscribe to my newsletter (ebrheum.com) and be sure to share the podcast with friends!By Michael Putman
…
continue reading
1
E97: Does allopurinol reduce CVD? The ALLHEART Study
10:07
10:07
Play later
Play later
Lists
Like
Liked
10:07
Nice quick RCT rundown this week, covering the ALLHEART study, a pragmatic RCT of urate lowering therapy to reduce cardiovascular disease. Quick listen for a useful teaching point! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01657-9/fulltextBy Michael Putman
…
continue reading
Today I cover the recently published long-COVID study from Norway. It's a great paper that challenges much of the prevailing wisdom. I think there are some interesting limitations, but anyone who sees post COVID patients (aka all of us) would do well to read it. Or have a listen here! PDF: https://jamanetwork.com/journals/jamanetworkopen/fullarticl…
…
continue reading
1
E95: Rituximab or Cyclophosphamide in ANCA Vasculitis
20:46
20:46
Play later
Play later
Lists
Like
Liked
20:46
Fun study this week from JAMA Network Open and the French Vasculitis Study Group. They used a target trial emulation (one of my favorites) to ask whether RTX > CYC in AAV (another one of my favorites). I tried to use this to compare between observational and randomized data. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799018…
…
continue reading
This week I hope to debunk one of rheumatology's "paradoxes." We love to talk about these and subject our fellows to memorizing them for the boards. We often use them to guide clinical practice, but I suspect that many "paradoxes" are actually the result of shoddy epidemiology. Todays' paper from JAMA dermatology covers one that I have heard freque…
…
continue reading
Today I'll be reading one of my recent newsletters! It's kind of a fun run-down of my anti-azathioprine stance. As I say in the piece, some patients may benefit from azathioprine and I am not saying it is an entirely useless drug or that nobody should ever prescribe it. Rather, I am just saying that it is likely the worst option for nearly every in…
…
continue reading
1
E92: Are muscle symptoms from statins imaginary?
10:36
10:36
Play later
Play later
Lists
Like
Liked
10:36
Today I review a recent large meta analysis of randomized controlled trials of statin use. Super interesting findings that have changed my clinical practice. Check out the paper here and listen to the episode! Paper: https://www.thelancet.com/article/S0140-6736(22)01545-8/fulltext "Internet driven cult" editorial: https://pubmed.ncbi.nlm.nih.gov/28…
…
continue reading
1
E91: Clinical Innovation in Rheumatology: Past, Present, and Future
19:56
19:56
Play later
Play later
Lists
Like
Liked
19:56
Change of pace today! I interviewed Jason Liebowitz and Phil Seo about their new book entitled "Clinical Innovation in Rheumatology: Past, Present, and Future." I thoroughly enjoyed the book and had a great time interviewing them about some of their "futuristic" topics. Grab the book (or better yet, have your division get some copies) at the link b…
…
continue reading
1
E90: There Is No Diagnosis of Exclusion in Rheumatology
6:45
6:45
Play later
Play later
Lists
Like
Liked
6:45
Quick episode this week to share an editorial I recently wrote with Jay Patel and Anisha Dua. We cover one of my least phrases in medicine, the "diagnosis of exclusion." Hope you enjoy! Find the original paper here: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keac278/6584804…
…
continue reading
1
E89: Vitamin D to Prevent Osteoporotic Fractures
11:02
11:02
Play later
Play later
Lists
Like
Liked
11:02
Exciting (negative) results from a large RCT on the podcast this week as well as a (mini) rant about how we should be spending our time as rheumatologists and the false security of ineffective treatments. Let me know what you think on twitter @ebhruem https://www.nejm.org/doi/full/10.1056/NEJMoa2202106…
…
continue reading
Interesting case-crossover study today evaluating the association between HCQ dosing and risk of SLE flares. Super worth your time to read the paper or listen to this episode! https://jamanetwork.com/journals/jama/article-abstract/2796634By Michael Putman
…
continue reading
Podcast is back! This week I discuss a pivotal RCT in dermatomyositis. Check it out and be sure to subscribe to my newsletter at ebrheum.com!By Michael Putman
…
continue reading
1
E86: Target Trials and Causality in Rheumatology
16:06
16:06
Play later
Play later
Lists
Like
Liked
16:06
Mixing it up again this week to discuss an editorial by Miguel Hernan and a systematic review of target trials in rheumatology. It's kind of a fun free-form stream of consciousness. Hope you enjoy! Links: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888052/ https://pubmed.ncbi.nlm.nih.gov/32381560/By Michael Putman
…
continue reading
Quick episode today. I wanted to share an editorial that was recently published in Rheumatology, where I and co-authors (Shannon Tai and Natalie Anumolu) discuss lessons from recent trials in AAV and SLE. Link to editorial: https://pubmed.ncbi.nlm.nih.gov/35438142/By Michael Putman
…
continue reading
1
E84: The JAKapocalypse (AKA ORAL Surveillance)
12:24
12:24
Play later
Play later
Lists
Like
Liked
12:24
After some delay, I finally get around to discussing ORAL-Surveillance, a post-marketing safety study of tofacitinib for rheumatoid arthritis. It's an incredibly important trial that will likely affect how all of us practice for the foreseeable future. Link to paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2109927…
…
continue reading
After a winter hiatus, the podcast is back! Today I wanted to dive into a 'hotbutton' issue - the question of whether (or not) COVID-19 vaccines "work" for patients with rheumatic diseases. My answer is an emphatic "yes," albeit with a few caveats. Here are the papers I discuss: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)000…
…
continue reading
Hello again! Snappy episode this week about the exciting LoVAS trial, which compared a reduced dose steroid taper for ANCA vasculitis. Be sure to drop by my website at ebrheum.com to subscribe to my newsletter!By Michael Putman
…
continue reading
1
E81: Vasculitis Guidelines E7: Takayasu Arteritis with Dr. Andy Abril
21:24
21:24
Play later
Play later
Lists
Like
Liked
21:24
In this episode, I talk with Dr. Andy Abril, Chair at the Division of Rheumatology at the Mayo Clinic in Jacksonville Florida. Dr. Abril is one of the lead authors for the 2021 ACR Guidelines on Takayasu’s arteritis. This project was done in partnership with the Vasculitis Foundation. To review the complete guidelines, visit https://dev.vasculitisf…
…
continue reading
1
E80: Vasculitis Guidelines E6 - Polyarteritis Nodosa with Dr. Jason Springer
19:37
19:37
Play later
Play later
Lists
Like
Liked
19:37
In this episode, I talk with Dr. Jason Springer, Co-Director of the Vanderbilt Vasculitis Center, about the guidelines for PAN He is one of the lead authors for the ACR/VF Guidelines for Polyarteritis Nodosa. This project was done in partnership with the Vasculitis Foundation. To review the complete guidelines, visit https://dev.vasculitisfoundatio…
…
continue reading
1
E79: Vasculitis Guidelines E5 - GCA with Dr. Mehrdad Maz
26:48
26:48
Play later
Play later
Lists
Like
Liked
26:48
On today's episode I discuss GCA with Dr. Mehrdad Maz. He is the Division Director of the Kansas University Allergy, Clinical Immunology and Rheumatology Section and served on the Steering Core Committee of the ACR-VF Vasculitis Treatment Guidelines. We cover a lot of great topics! This project was done in partnership with the Vasculitis Foundation…
…
continue reading
1
E78: Vasculitis Guidelines #4 - EGPA with Dr. Phil Seo
19:32
19:32
Play later
Play later
Lists
Like
Liked
19:32
In today's episode, I talk with Dr. Mehrdad Maz about the newly published guidelines for giant cell arteritis (GCA). Dr. Maz is the Division Director of the Kansas University Allergy, Clinical Immunology and Rheumatology Section. He serves on the Steering Core Committee of the ACR-VF Vasculitis Treatment Guidelines. This project was done in partner…
…
continue reading
1
E77: Vasculitis Guidelines #3 - ANCA Vasculitis with Dr. Sharon Chung
32:45
32:45
Play later
Play later
Lists
Like
Liked
32:45
The guidelines have finally arrived! I'm kicking off the series today with a conversation about the ANCA vasculitis guidelines. My guest is Dr. Sharon Chung, the director of the UCSF Vasculitis Clinic and the lead investigator on the ACR/Guideline committee. She provided a LOT of great insights; have a listen and let us know what you think! This pr…
…
continue reading
1
E76: Voclosporin for SLE Nephritis: The AURORA RCT
15:56
15:56
Play later
Play later
Lists
Like
Liked
15:56
Hopping in this week to round out my thoughts on ADVOCATE (avacopan in AAV) and covering the recently published AURORA trial for SLE nephritis. Back to the Vasculitis Guidelines Podcast after as soon as they are released!By Michael Putman
…
continue reading
1
E75: Vasculitis Guidelines Episode 2: Overview with Sharon Chung
21:53
21:53
Play later
Play later
Lists
Like
Liked
21:53
In this episode we'll be introducing the process by which the 2021 ACR/VF guidelines were produced. My guest is Dr. Sharon Chung. She's the director of the UCSF Vasculitis Clinic and the lead investigator on the guideline committee. Please follow along with future episodes - you can find me @ebrheum and the Vasculitis Foundation is at @vasculitisfo…
…
continue reading
1
E74: Vasculitis Guidelines Episode 1 - Joyce Kullman
10:32
10:32
Play later
Play later
Lists
Like
Liked
10:32
Welcome to the first episode of the Vasculitis Guidelines Podcast! In Episode 1, I interview Joyce Kullman, Executive Director of the Vasculitis Foundation, about collaborating with the ACR in updating these guidelines, and how patients with vasculitis will ultimately benefit from them. We discuss the complex process of updating these critical guid…
…
continue reading
1
E73: Introducing the Vasculitis Guidelines Podcast
1:41
1:41
Play later
Play later
Lists
Like
Liked
1:41
Quick update on a new series!By Michael Putman
…
continue reading
Steroid free remission! Or is it? This week I discuss a really exciting trial in ANCA vasculitis.By Michael Putman
…
continue reading
1
E71: MTX Discontinuation Post... Influenza Vaccination
13:16
13:16
Play later
Play later
Lists
Like
Liked
13:16
I stole some time to tackle a pressing issue for rheumatologists - to hold or not to hold immunosuppression in patients who are receiving a COVID19 vaccination. We obviously don't have any data on this, but I have always loved this study on influenza vaccination. PDFs at ebrheum.com/twts and follow me on twitter @ebrheum!…
…
continue reading
1
E70: Rheum4Debate - HCQ Levels Should Be Monitored in Patients with SLE
37:37
37:37
Play later
Play later
Lists
Like
Liked
37:37
We have a great show for you this week! Anisha Dua will be moderating a debate between myself and Max Konig on this motion: "Hydroxychloroquine levels should be monitored in patients with SLE." I learned a ton and thoroughly enjoyed it. Be sure to vote on the post-debate twitter poll to decide the winner!…
…
continue reading
This week I cover another of my meta-research projects, this one on systematic review and meta analysis (SRMA) growth as compared to randomized clinical trial (RCT) growth. Short and to the point - hope you enjoy! I highly recommend checking out the associated graphs - just take a quick peek at some point while listening. Find them on my twitter ha…
…
continue reading
1
E68: SELECT-CHOICE Upadacitinib vs Abatacept in RA
13:39
13:39
Play later
Play later
Lists
Like
Liked
13:39
Active comparator trial! Always my favorite. Lots of fun topics in this one, including noninferiority trials, crafty endpoints, and PROs. Check it out and let me know what you think! @ebrheumBy Michael Putman
…
continue reading
1
E67: Belimumab in Lupus Nephritis (BLISS-LN)
15:38
15:38
Play later
Play later
Lists
Like
Liked
15:38
Another day, another lupus trial, another round of endpoint shenanigans. Why does that matter? How big is the benefit from belimumab in SLE nephritis? Will this save lives and prevent ESRD / RRT? I try to tackle these issues this week and (hopefully) avoid getting myself in trouble. Hope you enjoy the episode! Let me know what you think @ebrheum on…
…
continue reading
Great paper to discuss this week - one that may be too good to believe? I highly recommend checking out the pdf first (ebrheum.com/twts) - their graphics are wonderful and do a great job of conveying their message. Also, check out the "2-5-10" rule that I referenced! This is required reading for anyone who rotates with me - easily one of the most u…
…
continue reading
Quick podcast this week that expands on issues I discuss in Episode 55. Go back and listen to that one first if you have time! I think this is an important issue and it's one I'd like to highlight. Let me know what you think @ebrheum and please share with friends!By Michael Putman
…
continue reading